Tag Archives: software

China PE Firm Invests Up to $40M Per Company In Medtech, Diagnostics, and Digital Health

19 Jul

A private equity firm headquartered in China with additional offices throughout China and Hong Kong provides venture capital and growth capital to growth-stage companies across various industries, including life sciences, Internet, consumables, software, and high technology sectors (i.e. drones). The firm is interested in all types of life science companies except drug development. The allocation size will vary, but the firm has the capability to allocate up to $40 million per company, depending on the opportunity. The investment is typically in form of equity, but convertible loan will be considered as well. The firm has an emphasis on technologies and products, and it is currently seeking new investment opportunities globally. Companies with a China angle will be a big plus.

The firm is currently seeking to invest in medical device, diagnostics, biotech R&D services and healthcare IT sectors. The firm is very opportunistic in terms of subsectors and indications. Currently the firm will not invest in companies targeting drug development. The firm will consider companies at all stages of development, from pre-clinical stage all through to commercial stage; however, the firm prefers companies in the business proven stage, where the product is on the market and may already have customer feedback.

The firm primarily invests in growth-stage private companies. The firm does not have specific requirements for companies’ management team or revenues. The firm will take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Newly Established VC Fund Invests in Innovative Digital Health and Medtech/Diagnostics Technologies with Software Components

12 Jul

A new venture fund started investing in pre-seed, seed and Series A rounds. The firm’s main investment areas are in companies that advance and improve human health through novel models of care delivery and in companies that are at the cutting-edge of frontier technology, such as neurotech, brain/machine interfaces, genomics and AI. The firm will consider digital health companies as well as diagnostics and medical device companies, as long as they have a software component. The firm will only invest in companies with disruptive technology, not incremental innovations. The firm will invest between $.1-1.5M in the initial investment, with the possibility of participating in following rounds. The firm is willing to lead or co-invest, has made 7 investments to date and is looking to invest in 4-6 companies a year.

The firm will consider digital health companies that are focused on improving patient care. Ideally, companies will already have a pilot with some outcomes-based data indicating traction. The firm is also interested in medical device companies, but will only invest if there is a significant software and/or radical innovation component. The firm will also consider diagnostics, such as genomics-based technologies, but not in vitro diagnostics. The firm will not invest in traditional therapeutics (i.e. small molecule or biologics) companies but will consider software-as-medicine and bioelectronic medicine.

Due to the firm’s preference for cutting-edge technology, the firm prefers that there be at least one technical expert in the company leadership. If acting as a lead investor, the firm will take a board or board observer seat. The firm prefers to be an active investor, providing multi-faceted support to portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: USA Venture Firm Seeks to Invest in Innovative Digital Health and Software-Based Diagnostic Companies

14 Jun

A venture capital firm with multiple offices in the USA is looking to invest in tech-driven companies that have at least one female on the leadership team. The firm invests in technology companies, including those in the healthcare sector, such as digital health and software-based diagnostics companies. The firm will invest primarily in series A-B rounds in USA-based companies with at least $1M in revenue. The firm will typically make initial investments between $1.5-5M.

The firm invests in technology companies in the digital health space that are solving some of the world’s greatest challenges. The firm particularly likes to see companies that are creating more affordable health solutions.

The firm does not require a board seat when investing, but may take one if the firm leads an investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Corporate Venture Arm of Leading Netherlands’ Telecom Service Provider Looking for Data and Software-Based Healthcare Technologies

19 Apr

Established in 2015, a corporate venture capital investment arm of a leading telecom and ICT service provider has interests in a variety of sectors in relation to their corporate activities, one of them being Digital Health. The firm manages a €70M revolving venture fund via which the firm invests in fast growing technology companies (Series A-C). In addition, the firm selectively invest in venture capital investment funds that complement the firm’ direct investment strategy and provide broader access to new technology companies and partnership opportunities. In January 2018, the firm for example initiated an early stage (seed) investment fund with multiple Dutch investors.

The firm aims to create value-creating partnerships with innovative technology companies providing access to capital, industry expertise, professional network and customer channels. The firm mainly focuses on opportunities based in Europe but is also interested to get in touch with companies which are located in USA and Canada, as long as they have an interest in expanding their commercial activities to the Netherlands. The firm’s initial ticket size typically ranges from €0.5M to €3M for minority stakes, building long-term partnerships, ultimately aiming for external exits, not acquisitions. The firm is open to both leading and co-investing, depending on the proposition. While the firm does not aim for a specific number of investments, the firm has made 6 investments per year since establishment.

The firm is highly interested in B2B/B2C software-based technology companies. The firm will only consider medical or diagnostic hardware companies that have a strong data or software component. The firm is especially interested in technologies that enable easier and smarter health management for patients and or medical professionals (i.e. self-monitoring devices for chronic disease management with real-time data accessibility, preventative healthcare, etc.). The firm is also interested in propositions that focus on (cyber) security solutions and or propositions that create efficiencies/cost-reductions within health organizations.

The firm seeks technologies that have a strategic fit or enough potential for a future collaboration with the firm’s health business, that fall under the firm’s sectors of interest. The firm prefers to work with management teams with a proven track record and wants to see market traction/validation, with at least €0.5M in annual revenues.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: